The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Open accessAbstract
Tissues from rhesus monkeys were screened by PCR for the presence of sequences homologous to known adeno-associated virus (AAV) serotypes 1–6. DNA spanning entire rep-cap ORFs from two novel AAVs, called AAV7 and AAV8, were isolated. Sequence comparisons among these and previously described AAVs revealed the greatest divergence in capsid proteins. AAV7 and AAV8 were not neutralized by heterologous antisera raised to the other serotypes. Neutralizing antibodies to AAV7 and AAV8 were rare in human serum and, when present, were low in activity. Vectors formed with capsids from AAV7 and AAV8 were generated by using rep and inverted terminal repeats (ITRs) from AAV2 and were compared with similarly constructed vectors made from capsids of AAV1, AAV2, and AAV5. Murine models of skeletal muscle and liver-directed gene transfer were used to evaluate relative vector performance. AAV7 vectors demonstrated efficiencies of transgene expression in skeletal muscle equivalent to that observed with AAV1, the most efficient known serotype for this application. In liver, transgene expression was 10- to 100-fold higher with AAV8 than observed with other serotypes. This improved efficiency correlated with increased persistence of vector DNA and higher number of transduced hepatocytes. The efficiency of AAV8 vector for liver-directed gene transfer of factor IX was not impacted by preimmunization with the other AAV serotypes. Vectors based on these novel, nonhuman primate AAVs should be considered for human gene therapy because of low reactivity to antibodies directed to human AAVs and because gene transfer efficiency in muscle was similar to that obtained with the best known serotype, whereas, in liver, gene transfer was substantially higher than previously described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most likely due to the high prevalence of natural AAV8 and AAV9 infections in rhesus macaques.53,54”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For all other experiments we focused on cy5 as it is a variant of AAV7 that, based on its extremely weak immunogenicity, has been proposed to have a strong potential to be developed as a clinical gene therapy vector (Gao et al., 2002).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as Gao et al., 2002
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“since neutralizing antibodies to AAV7 are rare in human serum (Gao et al., 2002).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as Gao et al., 2002
In the citing paper
“Pre-existing antibodies against capsids can signi fi cantly inhibit ef fi cient AAV transduction in NHPs (29) and humans (12).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684
Self-citationGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
Self-citationHoggan, M. D., Blacklow, N. R., & Rowe, W. P. (1966) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.55.6.1467 · Cited by 536
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470
Self-citationRutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452
Auricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403
Zhang, Y., Chirmule, N., Gao, G.-P., Qian, R., Croyle, M., Joshi, B., Tazelaar, J., & Wilson, J. M. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0329 · Cited by 376
Self-citation
Research works printed but not linked: 2
- N Muzyczka, K I Berns Fields Virology, eds D M Knipe, P M Howley (Lippincott Williams & Wilkins, Philadelphia) 2, 2327–2359 (2001).
- N R Blacklow, M D Hoggan, W P Rowe J Natl Cancer Inst 40, 319–327 (1968).
Cited by
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
Metadata
- Authors
- Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M.
- Affiliations
- Institute for Human Gene Therapy and Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104; and Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104
- The Wistar Institute (US)
- Corresponding author
- Wilson, James M.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-08-21
- Volume
- 99
- Issue
- 18
- Pages
- 11854-11859
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC129358
- OpenAlex
- W2047608515
- Cited by
- 1,520
- References
- 36
- Citations by year
- 2026: 27 · 2025: 34 · 2024: 42 · 2023: 46 · 2022: 42 · 2021: 41 · 2020: 50 · 2019: 67 · 2018: 56 · 2017: 56 · 2016: 38 · 2015: 69 · 2014: 65 · 2013: 77 · 2012: 70
- FWCI
- 41.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cystic Fibrosis Foundation
- GlaxoSmithKline
- University of Pennsylvania
- National Institutes of Health (P30 DK)
- National Heart, Lung, and Blood Institute (P01 HL 59407-03, P01HL059407)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK 47757-09, P30DK047757)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, AAV8, rhesus monkeys, gene therapy vectors, neutralizing antibodies, liver-directed gene transfer, skeletal muscle gene transfer, factor IX, transgene expression, vector persistence, inverted terminal repeats
- MeSH terms
- Dependovirus, Amino Acid Sequence, Animals, Base Sequence, Capsid, Genetic Vectors, Humans, Macaca mulatta, Mice, Inbred C57BL, Molecular Sequence Data, Genetic Therapy, Sequence Homology, Amino Acid, DNA Primers, Gene Transfer Techniques, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. https://app.cochat.ai/papers/10.1073/pnas.182412299
- The paper
- Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.182412299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.